BRPI0507435A - compostos de piperidinilcarbonilpirrolidinas, processos para a preparação do mesmo,composição farmacêutica e uso como agonistas de melanocortina - Google Patents

compostos de piperidinilcarbonilpirrolidinas, processos para a preparação do mesmo,composição farmacêutica e uso como agonistas de melanocortina

Info

Publication number
BRPI0507435A
BRPI0507435A BRPI0507435-5A BRPI0507435A BRPI0507435A BR PI0507435 A BRPI0507435 A BR PI0507435A BR PI0507435 A BRPI0507435 A BR PI0507435A BR PI0507435 A BRPI0507435 A BR PI0507435A
Authority
BR
Brazil
Prior art keywords
processes
compounds
preparation
pharmaceutical composition
piperidinylcarbonylpyrrolidines
Prior art date
Application number
BRPI0507435-5A
Other languages
English (en)
Inventor
Andrew Antony Calabrese
David Sebastien Fradet
David Hepworth
Mark Lansdell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34864830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507435(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0412417A external-priority patent/GB0412417D0/en
Priority claimed from GB0425530A external-priority patent/GB0425530D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0507435A publication Critical patent/BRPI0507435A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

COMPOSTOS DE PIPERIDINILCARDONIL-PIRROLIDINAS, PROCESSOS PARA A PREPARAçãO DO MESMO, COMPOSIçãO FARMACêUTICA E USO COMO AGONISTAS DE MELA-NOCORTINA. A presente invenção refere-se a uma classe de agonistas de MCR4 de melanocortina da fórmula geral (l) em que R¬, R¬, R¬, R¬, e R¬ são com aqui definido e especialmente a compostos de agonista de MCR4 seletivos, a seu uso na medicina, às composições que os contêm, a processos para sua preparação e a intermediários empregados em tais processos.
BRPI0507435-5A 2004-02-04 2005-01-26 compostos de piperidinilcarbonilpirrolidinas, processos para a preparação do mesmo,composição farmacêutica e uso como agonistas de melanocortina BRPI0507435A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0402492.3A GB0402492D0 (en) 2004-02-04 2004-02-04 Pharmaceutically active compounds
GB0412417A GB0412417D0 (en) 2004-06-03 2004-06-03 Pharmaceutically active compounds
GB0425530A GB0425530D0 (en) 2004-11-19 2004-11-19 Pharmaceutically active compounds
PCT/IB2005/000208 WO2005077935A1 (en) 2004-02-04 2005-01-26 Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists

Publications (1)

Publication Number Publication Date
BRPI0507435A true BRPI0507435A (pt) 2007-07-03

Family

ID=34864830

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507435-5A BRPI0507435A (pt) 2004-02-04 2005-01-26 compostos de piperidinilcarbonilpirrolidinas, processos para a preparação do mesmo,composição farmacêutica e uso como agonistas de melanocortina

Country Status (25)

Country Link
EP (1) EP1716135B1 (pt)
JP (1) JP4031814B2 (pt)
KR (1) KR100830763B1 (pt)
CN (1) CN1930146A (pt)
AP (1) AP2006003699A0 (pt)
AR (1) AR048232A1 (pt)
AT (1) ATE511507T1 (pt)
AU (1) AU2005213538A1 (pt)
BR (1) BRPI0507435A (pt)
CA (1) CA2555800C (pt)
CR (1) CR8545A (pt)
EA (1) EA011159B1 (pt)
EC (1) ECSP066751A (pt)
GB (1) GB0402492D0 (pt)
GE (1) GEP20084361B (pt)
IL (1) IL177004A0 (pt)
MA (1) MA28348A1 (pt)
NL (1) NL1028193C2 (pt)
NO (1) NO20063944L (pt)
PA (1) PA8623101A1 (pt)
PE (1) PE20050772A1 (pt)
TW (1) TWI300066B (pt)
UY (1) UY28737A1 (pt)
WO (1) WO2005077935A1 (pt)
ZA (1) ZA200606236B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
EP1940842B1 (en) * 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
AU2006304305B2 (en) * 2005-10-18 2010-04-01 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CN101426782B (zh) * 2006-02-23 2012-10-31 辉瑞股份有限公司 黑皮质素4型受体激动剂哌啶羰基吡咯烷
WO2007096763A2 (en) * 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
ME01579B (me) 2007-08-07 2014-09-20 Takeda Pharmaceuticals Co Derivati pirolidin-2-ona kao modulatori androgenskih receptora
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
PL3150578T3 (pl) * 2014-05-29 2021-07-19 Mitsubishi Tanabe Pharma Corporation Nowy związek pirolidynowy i zastosowanie jako agonisty receptora melanokortyny
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EP3333165B1 (en) * 2015-08-04 2019-09-18 Astellas Pharma Inc. Piperazine derivative
CN112694436B (zh) * 2020-12-30 2022-07-08 济南周行医药科技有限公司 一种槟榔碱的合成方法
BR112023022863A2 (pt) * 2021-05-06 2024-01-23 Lg Chemical Ltd Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo
CN114211258B (zh) * 2021-11-04 2023-09-26 江阴市大久金属科技有限公司 高精密无缝钢管制备工艺

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439152C (en) * 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE60215132T2 (de) * 2001-02-28 2007-08-23 Merck & Co., Inc. Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten

Also Published As

Publication number Publication date
PA8623101A1 (es) 2006-05-16
PE20050772A1 (es) 2005-10-31
ZA200606236B (en) 2008-04-30
JP4031814B2 (ja) 2008-01-09
KR20060127125A (ko) 2006-12-11
GEP20084361B (en) 2008-04-29
NL1028193A1 (nl) 2005-08-08
CN1930146A (zh) 2007-03-14
CA2555800A1 (en) 2005-08-25
EA200601279A1 (ru) 2006-12-29
EA011159B1 (ru) 2009-02-27
UY28737A1 (es) 2005-09-30
AU2005213538A1 (en) 2005-08-25
NL1028193C2 (nl) 2006-04-20
MA28348A1 (fr) 2006-12-01
ATE511507T1 (de) 2011-06-15
EP1716135A1 (en) 2006-11-02
KR100830763B1 (ko) 2008-05-19
CA2555800C (en) 2010-06-15
IL177004A0 (en) 2006-12-10
AP2006003699A0 (en) 2006-08-31
TW200526625A (en) 2005-08-16
ECSP066751A (es) 2006-11-16
CR8545A (es) 2007-09-03
AR048232A1 (es) 2006-04-12
GB0402492D0 (en) 2004-03-10
WO2005077935A1 (en) 2005-08-25
EP1716135B1 (en) 2011-06-01
NO20063944L (no) 2006-10-31
JP2007534668A (ja) 2007-11-29
TWI300066B (en) 2008-08-21

Similar Documents

Publication Publication Date Title
BRPI0507435A (pt) compostos de piperidinilcarbonilpirrolidinas, processos para a preparação do mesmo,composição farmacêutica e uso como agonistas de melanocortina
BRPI0708490B8 (pt) composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto
BRPI0410946A (pt) derivados de 2-(6-amino-piridin-3-il)-2-hidroxietilamina como agonistas de receptores adrenérgicos beta 2
BRPI0713443A2 (pt) Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
BRPI0713367A2 (pt) composto, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta
BR122017015106B8 (pt) estrutura de cristal de formula 1b e composição farmacêutica
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0717156B8 (pt) inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
BRPI0519148A2 (pt) inibidores de homodimerizaÇço de myd88
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
CU20060039A7 (es) Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
AR109224A2 (es) Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
BRPI0518096A (pt) composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos
BR0012478A (pt) Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
BRPI0610205A2 (pt) piperidinas 3,4-substituìdas como inibidores da renina
BRPI0512986A (pt) novos derivados de hidantoìna

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6 ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.